Rx License-Rx

TAB-2412

Gs Alpha LoxP (Gnastm1Lsw) Mouse Model for Metabolism Studies

Generation of a floxed Gnsa gene for the G-protein Gs alpha (G s alpha) for the construction of conditional knockout mice. The heterotrimeric G protein G s alpha couples many receptors to adenylyl cyclase and is essential for hormone-stimulated cAMP generation. Previous mouse models with germ-line mutations in Gnas , the gene that encodes G s alpha had limited usefulness in trying to decipher the role of G s alpha pathways in specific tissues since only heterozygotes were viable and could be analyzed. Analysis was further complicated by the fact that G s alpha is imprinted expressed in many metabolically active tissues. G s alpha-floxed mice were generated so that the metabolic effects of G s alpha deficiency could be examined in specific tissues. Exon1, which is specific for G s alpha, was surrounded with loxP recombination sites. Liver-specific knockouts of G s alpha were obtained by mating the G s alpha-floxed mice with albumin...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Cardiometabolic

Indication: Liver disease

Modality: Biologic

Focus tags: Cardiometabolic

Technology tags: Biologic

Mechanism:

Development stage: Preclinical

Patent status: Research Material

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Cardiometabolic. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Liver disease. Public description: Generation of a floxed Gnsa gene for the G-protein Gs alpha (G s alpha) for the construction of conditional knockout mice. The heterotrimeric G protein G s alpha couples many receptors to adenylyl cyclase and is essential for.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Indication narrowing plus an outsourced translational evidence package

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Novartis — Broad modality appetite and academic-origin BD history. Takeda — Translational science focus and partnership-friendly structure. Sanofi — Immunology, rare disease, and platform-technology BD appetite.

Development Strategy to Increase PoS

First indication: Liver disease

Study design: One decisive preclinical or analytical validation package with a hard go/no-go threshold.

Key experiments Validate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence package Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Indication narrowing plus an outsourced translational evidence package

Best next experiment: Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.